Company / R&D Expense
Caribou Biosciences, Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$109.4M
FY2025
5-year range
$23.6M / $112.1M
FY2021-FY2025
Trend
-2.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $82M to $109M over the past 2 years.
Based on SEC 10-K filings.
$109M in FY2025 with a 3-year CAGR of +27.9%.
Improved from $82M to $109M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +27.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +27.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 2.4% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $109.4M | -2.4% |
| FY2024 | $112.1M | +36.3% |
| FY2023 | $82.2M | +57.4% |
| FY2022 | $52.3M | +121.1% |
| FY2021 | $23.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026